{"sequenceId":"845363540389","id":"34207155193","language":"English","title":"resTORbio (TORC) versus Its Peers Head to Head Review","content":"resTORbio (NASDAQ: TORC) is one of 493 publicly-traded companies in the “Pharmaceutical preparations” industry, but how does it contrast to its rivals? We will compare resTORbio to similar businesses based on the strength of its earnings, risk, institutional ownership, profitability, dividends, analyst recommendations and valuation.    Earnings & Valuation    Get resTORbio alerts:      This table compares resTORbio and its rivals gross revenue, earnings per share and valuation.      Gross Revenue  Net Income  Price/Earnings Ratio  resTORbio  N/A  -$33.77 million  -1.18  resTORbio Competitors  $2.01 billion  $135.76 million  -3.79   resTORbio’s rivals have higher revenue and earnings than resTORbio. resTORbio is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.    Analyst Recommendations    This is a breakdown of recent ratings for resTORbio and its rivals, as reported by MarketBeat.    Sell Ratings  Hold Ratings  Buy Ratings  Strong Buy Ratings  Rating Score  resTORbio  0  0  4  0  3.00  resTORbio Competitors  3040  9201  22171  645  2.58   resTORbio currently has a consensus price target of $29.25, suggesting a potential upside of 195.16%. As a group, “Pharmaceutical preparations” companies have a potential upside of 37.51%. Given resTORbio’s stronger consensus rating and  higher probable upside, research analysts plainly believe resTORbio is more favorable than its rivals.    Insider & Institutional Ownership    39.3% of resTORbio shares are held by institutional investors. Comparatively, 47.5% of shares of all “Pharmaceutical preparations” companies are held by institutional investors. 15.8% of shares of all “Pharmaceutical preparations” companies are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.    Profitability    This table compares resTORbio and its rivals’ net margins, return on equity and return on assets.    Net Margins  Return on Equity  Return on Assets  resTORbio  N/A  N/A  N/A  resTORbio Competitors  -2,974.57%  -159.20%  -30.61%   Summary    resTORbio beats its rivals on 7 of the 12 factors compared.    About resTORbio    resTORbio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of aging-related diseases. Its lead program is targeting the selective inhibition of TORC1, an evolutionary conserved pathway that contributes to the decline in function of multiple organ systems, including the immune, cardiac, and neurologic systems. The company's lead drug candidate RTB101 is a selective, orally administered, TORC1 inhibitor, which is being tested in a Phase 2b clinical trial as a first in-class immunotherapy for reducing the incidence of respiratory tract infections in the elderly by enhancing the function of the immune system. It also intends to develop RTB101 for additional aging-related indications, such as heart failure or neurodegenerative diseases. The company was founded in 2016 and is based in Boston, Massachusetts.","contentWithMarkup":"resTORbio (NASDAQ: TORC) is one of 493 publicly-traded companies in the “Pharmaceutical preparations” industry, but how does it contrast to its rivals? We will compare resTORbio to similar businesses based on the strength of its earnings, risk, institutional ownership, profitability, dividends, analyst recommendations and valuation.    Earnings & Valuation    Get resTORbio alerts:      This table compares resTORbio and its rivals gross revenue, earnings per share and valuation.      Gross Revenue  Net Income  Price/Earnings Ratio  resTORbio  N/A  -$33.77 million  -1.18  resTORbio Competitors  $2.01 billion  $135.76 million  -3.79   resTORbio’s rivals have higher revenue and earnings than resTORbio. resTORbio is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.    Analyst Recommendations    This is a breakdown of recent ratings for resTORbio and its rivals, as reported by MarketBeat.    Sell Ratings  Hold Ratings  Buy Ratings  Strong Buy Ratings  Rating Score  resTORbio  0  0  4  0  3.00  resTORbio Competitors  3040  9201  22171  645  2.58   resTORbio currently has a consensus price target of $29.25, suggesting a potential upside of 195.16%. As a group, “Pharmaceutical preparations” companies have a potential upside of 37.51%. Given resTORbio’s stronger consensus rating and  higher probable upside, research analysts plainly believe resTORbio is more favorable than its rivals.    Insider & Institutional Ownership    39.3% of resTORbio shares are held by institutional investors. Comparatively, 47.5% of shares of all “Pharmaceutical preparations” companies are held by institutional investors. 15.8% of shares of all “Pharmaceutical preparations” companies are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.    Profitability    This table compares resTORbio and its rivals’ net margins, return on equity and return on assets.    Net Margins  Return on Equity  Return on Assets  resTORbio  N/A  N/A  N/A  resTORbio Competitors  -2,974.57%  -159.20%  -30.61%   Summary    resTORbio beats its rivals on 7 of the 12 factors compared.    About resTORbio    resTORbio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of aging-related diseases. Its lead program is targeting the selective inhibition of TORC1, an evolutionary conserved pathway that contributes to the decline in function of multiple organ systems, including the immune, cardiac, and neurologic systems. The company's lead drug candidate RTB101 is a selective, orally administered, TORC1 inhibitor, which is being tested in a Phase 2b clinical trial as a first in-class immunotherapy for reducing the incidence of respiratory tract infections in the elderly by enhancing the function of the immune system. It also intends to develop RTB101 for additional aging-related indications, such as heart failure or neurodegenerative diseases. The company was founded in 2016 and is based in Boston, Massachusetts.","tags":[],"publishedDate":"2018-06-03T03:31:04Z","harvestDate":"2018-06-02T21:35:22Z","estimatedPublishedDate":"2018-06-02T21:35:22Z","url":"http://ct.moreover.com/?a=34207155193&p=1u0&v=1&x=aMsp4O5s8BZSd0dq1TE1sQ","originalUrl":"https://ledgergazette.com/2018/06/02/reviewing-restorbio-torc-and-its-peers-3.html","outboundUrls":[],"wordCount":"417","dataFormat":"text","duplicateGroupId":"34207155193","media":{"audio":[],"images":[],"video":[],"logo":[]},"publishingPlatform":{},"adultLanguage":"false","topics":[{"name":"Business latest","group":"Business"}],"companies":[{"name":"resTORbio Inc","symbol":"TORC","exchange":"NAS","isin":"US76133L1035","titleCount":0,"contentCount":1,"primary":true},{"name":"resTORbio Inc","symbol":"1IJ","exchange":"FRA","isin":"US76133L1035","titleCount":0,"contentCount":1,"primary":true}],"author":{"name":"Sebastian Weber","publishingPlatform":{}},"licenses":[{"name":"Publicly Available"}],"source":{"name":"Ledger Gazette","homeUrl":"https://ledgergazette.com","category":"Trade","editorialRank":"3","industry":"Banking & Finance","location":{"country":"United States","countryCode":"US","region":"Americas","subregion":"Northern America"},"feed":{"id":"599564993","name":"Ledger Gazette","mediaType":"News","tags":[],"language":"Unassigned","dataFormat":"text","rank":{"inboundLinkCount":"1137"},"inWhiteList":"true","autoTopics":[],"editorialTopics":["Professional","Business"],"genre":"General"}},"es_id":86991809}